key: cord-0895272-0wbyej9n
authors: Mustanski, Brian; Saber, Rana; Ryan, Daniel T.; Benbow, Nanette; Madkins, Krystal; Hayford, Christina; Newcomb, Michael E.; Schrock, Joshua M.; Vaught, Lauren A.; Reiser, Nina L.; Velez, Matthew P.; Hsieh, Ryan R.; Demonbreun, Alexis R.; D'Aquila, Richard; McNally, Elizabeth M.; McDade, Thomas W.
title: Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago
date: 2021-10-31
journal: Ann Epidemiol
DOI: 10.1016/j.annepidem.2021.10.006
sha: 293b3cc389d1d3ec1b1d813fb4138d3358f3a0db
doc_id: 895272
cord_uid: 0wbyej9n

To date, COVID-19 case rates are disproportionately higher in Black and Latinx communities across the US, leading to more hospitalizations and deaths in those communities. These differences in case rates are evident in comparisons of Chicago neighborhoods with differing race/ethnicities of their residents. Disparities could be due to neighborhoods with more adverse health outcomes associated with poverty and other social determinants of health experiencing higher prevalence of SARS-CoV-2 infection or due to greater morbidity and mortality resulting from equivalent SARS-CoV-2 infection prevalence. We surveyed five pairs of adjacent ZIP codes in Chicago with disparate COVID-19 case rates for highly specific and quantitative serological evidence of any prior infection by SARS-CoV-2 to compare with their disparate COVID-19 case rates. Dried blood spot samples were self-collected at home by internet-recruited participants in summer 2020, shortly after Chicago's first wave of the COVID-19 pandemic. Pairs of neighboring ZIP codes with very different COVID-19 case rates had similar seropositivity rates for anti-SARS-CoV-2 receptor binding domain IgG antibodies. Overall, these findings of comparable exposure to SARS-CoV-2 across neighborhoods with very disparate COVID-19 case rates are consistent with social determinants of health, and the co-morbidities related to them, driving differences in COVID-19 rates across neighborhoods.

infection prevalence. We surveyed five pairs of adjacent ZIP codes in Chicago with disparate COVID-19 case rates for highly specific and quantitative serological evidence of any prior infection by SARS-CoV-2 to compare with their disparate COVID-19 case rates. Dried blood spot samples were self-collected at home by internet-recruited participants in summer 2020, shortly after Chicago's first wave of the COVID-19

pandemic. Pairs of neighboring ZIP codes with very different COVID-19 case rates had similar seropositivity rates for anti-SARS-CoV-2 receptor binding domain IgG antibodies. Overall, these findings of comparable exposure to SARS-CoV-2 across neighborhoods with very disparate COVID-19 case rates are consistent with social determinants of health, and the co-morbidities related to them, driving differences in COVID-19 rates across neighborhoods.

The US has led the world in numbers of SARS-CoV-2 infections (1) with Chicago as one of the epicenters with 241,655 cases of COVID-19 resulting in 4,909 deaths by February 20, 2021 (2) . From early in the pandemic, stark racial/ethnic disparities were evident in COVID-19 deaths. Subsequent analyses of public health surveillance data further explicated the nature of COVID-19 racial disparities, with many studies showing that communities with more Black or Latinx residents had higher case and mortality rates (3) . Studies examining the drivers of these racial/ethnic disparities have found relatively consistent associations with residential segregation of economic disadvantage, proportion of essential workers, and crowded living conditions (4) (5) (6) .

There have been inconsistent results across studies regarding whether comorbidities mediate the observed racial/ethnic disparities (3, 7, 8) .

The analyses demonstrating such disparities mostly relied on molecular testing to diagnose acute, symptomatic COVID-19 illness by detecting SARS-CoV-2 RNA in nasal and nasopharyngeal swabs (9) . However, from the beginning of the pandemic until the present, acute viral diagnostic testing has not always been readily accessible to all. This could limit accurate estimation of the COVID-19 case rate and epidemiological patterns of SARS-CoV-2 spread by not identifying minimally symptomatic and asymptomatic, but potentially infectious, cases (10) (11) (12) (13) . Many infections are asymptomatic or minimally symptomatic, although still capable of transmitting SARS-CoV-2 to others (10) . A complementary epidemiological approach is serological testing to detect antibodies against the virus (14, 15) . Virus protein-specific antibodies emerge within weeks after infection, and subsequent IgG specific antibodies remain detectable for 4 or more months after infection, depending on assay sensitivity and specificity. This is much longer than the several weeks that airway virus RNA remains detectable (16) (17) (18) (19) after recovery from symptoms (20) . Thus, serology has potential to identify infections long after their initiation, independent of clinical diagnosis and symptom experience, potentially providing a fuller epidemiologic assessment of the pandemic. Assessment of all SARS-CoV-2 exposures by antibody detection can also test the hypothesis that risk of the viral infection itself varies by race/ethnicity, rather than only a subsequent COVID-19 illness being associated with race/ethnicity. Fewer seroprevalence studies of racial and geographic disparities have been reported to date, relative to comparisons of virus RNA-based COVID-19 case surveillance. These studies suggest there are racial/ethnic disparities in SARS-CoV-2 infection, although they have some limitations and inconsistent results. One early study of fingerstick blood specimens collected at grocery stores in New York state observed significantly higher prevalence of IgG antibodies to the SARS-CoV-2 nucleocapsid protein, assessed as detectable versus not detectable antibody, among Latinx, Black, and Asian adults relative to white adults (21) . Another study in Baton Rouge using the qualitative Abbott SARS-CoV-2 anti-nucleocapsid IgG nucleoprotein enzyme-linked immunosorbent assays (ELISA) assay (ARCHITECT TM platform) was not indubitably confirmatory, as it found much smaller differences. Weighted seroprevalence was 9.8% among participants who were Black, 7.1% multiracial, 5.5% Asian, 4.5% White, and 5.3% Hispanic; confidence intervals were non-overlapping except for Asian and Hispanic (22) . Both reports had the limitation that the qualitative anti-nucleocapsid antibody assays used have been reported to not be as sensitive and specific as quantitative ELISA detection of anti-SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) IgG. Previous reports suggest that an anti-RBD IgG assay exhibits superior performance compared to an anti-nucleocapsid IgG assay (19, (23) (24) (25) (26) . These two earlier assessments of racial/ethnic disparities in seroprevalence also relied on inperson collection of samples at a clinical care or research site, which limits reach and coverage during varying pandemic mitigations such as stay at home orders similarly to acute virus diagnostic testing.

In Chicago, like many cities, there are large differences in documented rates of COVID-19 cases and fatalities across neighborhoods that vary in their racial/ethnic and socioeconomic composition (2) . However, the lack of comprehensive seroprevalence assessments reported to date has not yet enabled analysis of whether SARS-CoV-2

infections are similarly disparate. The current study tested the hypothesis that geographic disparities in COVID-19 case rates will be mirrored in seroprevalence rates, using a more sensitive, specific, and quantitative antibody assay than the earlier reports (21, 22) . Moreover, the antibody assay used here is not dependent upon access to inperson testing at care or research sites. To achieve this, we utilized dried blood spots (DBS) collected in the home setting using a simple finger prick method. This followed web-and mass media-facilitated participant recruitment and online screening/consenting. After blood collection, participants' DBS cards were returned to the laboratory for testing in pre-paid mailers. We used a previously described DBSbased quantitative ELISA for IgG to the RBD of the SARS-CoV-2 protein (27) . Our study design offered a strong opportunity to confirm the hypothesis that geographic disparities would be similar in molecular diagnostic and serosurveillance assays across 5 pairs of Chicago ZIP codes that both bordered one another and had very different COVID-19 case rates. Results instead suggest there are differences in COVID-19 illness between these neighborhoods, but not SARS-CoV-2 infection.

All research activities were implemented under conditions of informed consent with protocols approved by the institutional review board of the university where the authors are primarily affiliated. Study data were collected and managed using REDCap electronic data capture tools (28) .

To select ZIP code pairs, COVID-19 cumulative case rates by ZIP code were obtained from Chicago Department of Public Health's (CDPH) COVID-19 website (2).

Additional health, socio-economic, and demographic ZIP code level data were selected from US Census Bureau American Community Survey (29) and the Chicago Health Atlas (listed in Table 2 ) (30) . CDPH calculated quintiles for COVID-19 cumulative case rate by ZIP code for the week of 4/26/20-5/2/20. Low case rate ZIP codes (category 1 or 2) that were adjacent to high case rate ZIP codes (category 4 or 5) were identified (9 groups). Some groups had multiple eligible ZIP codes (e.g., 60615 could be paired with 60609 or 60653) in which case pairs with the biggest difference in case rates were selected. To narrow the sample from 9 to 5 ZIP code pairs a map highlighting possible ZIP codes was created, and pairs were selected that maximized geographic distribution throughout the city.

To achieve a diverse representation of residents of these ZIP codes, participants were recruited using two approaches. First, community-based participants (n = 1,509) were recruited from ten ZIP codes in Chicago through organic and paid social media advertising (e.g., Facebook, Nextdoor), outreach to local businesses and community leaders (e.g., posters in community-based organizations, libraries, salons; alderman newsletters), news articles about the study reported in city-wide news media (e.g., Chicago Tribune article, WGN News interview), and participant referrals to neighbors.

Participants were screened for eligibility, which included ZIP code residence and age of 18 years or over. To assure racial and gender diversity within the sample, enrollment of women and white participants (groups that disproportionately completed the screener) was adaptively matched to enrollment of men and racial-minority participants within each ZIP code. Second, staff, students and faculty from the Northwestern University's Feinberg School of Medicine (FSM) in Chicago, IL were sent an email describing the study with a link to the website (n = 158 who lived in one of the 10 study ZIP codes).

Eligible participants were invited to complete a questionnaire regarding health status, including COVID-19 symptoms. Community participants received materials for DBS collection through the United States Postal Service (USPS) and returned their test kits using prepaid USPS envelopes provided to them by the study team. Those affiliated with FSM were given a specific time to collect DBS kits in person and were instructed to return their completed kits to the same location. The research team developed a video that explained to participants all of the steps of DBS collection and return (31). Sample collection occurred between June 24 and November 23, 2020.

We measured antibodies to RBD because previous studies have reported better sensitivity and specificity for SARS-CoV-2 infection detection than seen with antinucleocapsid antibodies (19, (23) (24) (25) (26) . Anti-RBD antibodies have infrequent and low-level cross-reactivity to other seasonal human coronaviruses (32, 33) , an advantage relative to detection of antibodies to other SARS-CoV-2 proteins. The ELISA protocol we used was modified from a widely used serum-based ELISA protocol with FDA emergency use authorization (34) and cross-reactivity of non-SARS-CoV-2 antibodies (Varicella, Influenza, HSV, Rubella, Hepatitis, HIV, elevated IgG, elevated IGM, CMV) against RBD was not detected (35) . The assay has been validated for DBS sample collection with 96.6% of self-reported clinically confirmed COVID-19 positive samples seropositive and 100% of pre-pandemic (2018) COVID-19 negative control samples seronegative (27) . Samples were run in duplicate, reported as the average, and normalized to the CR3022 antibody with known affinity (36) . A value >0.39µg/ml CR3022 was considered seropositive.

Unadjusted and adjusted binomial logistic regression was performed to compare seroprevalence within each ZIP code pair. Covariates included demographic variables associated with COVID-19 case rates in Chicago (i.e., age, race/ethnicity, and gender (2)) and prior COVID-19 testing result as differences in access or utilization of COVID-19 diagnostic testing within ZIP codes could drive differences in seropositivity.

Geographical information system (GIS) analyses were conducted using ArcGIS Pro 2.6.2. Only participants who were geocoded using the StreetAddress or AddressPoint locator and were geocoded to the ten ZIP codes chosen for analysis were included in the geospatial analysis (n = 1,666). Data sources for GIS data are indicated in Table 2 . Table 1 reports sample characteristics. A slight majority of the sample was non-Latinx white (54.3%), most had never tested for COVID-19 (71.4%), and the sample was heterogenous in terms of employment-based SARS-CoV-2 exposure risk. Overall, the seroprevalence in the sample was 18.7%. As indicated by non-overlapping confidence intervals in estimates in Table 1 , seroprevalence was significantly higher in Latinx (25.9%) than White non-Latinx (15.6%) and Asian, non-Latinx (15.8%), and in those who had previously tested COVID-19 positive (90.2%) than those who had never tested (17.2%) or tested negative (16.1%). Table 3 shows odds ratios of seroprevalence within each of the 5 ZIP code pairs, none of which were significant; even trends across pairs did not support the hypothesis that adjacent ZIP codes with higher case rates trended towards a higher seroprevalence based on antibody testing. Adjustments with individual-level covariates that differ across ZIP codes (e.g., race/ethnicity) did alter some point estimates but did not change the pattern of significance of results. Analyses weighting data to census characteristics (not shown) also did not alter the pattern or significance of findings.

In this study we sought to test the hypothesis that geographic differences in epidemiology of COVID-19 based on case reports would be confirmed in a seroprevalence study of IgG antibodies to the SARS-CoV-2 spike protein. Our comparison of 5 adjacent ZIP codes with substantially different COVID-19 case rates at the time of selection did not confirm this hypothesis. In unadjusted, adjusted, and weighted analyses, there were no significant differences in seroprevalence between ZIP codes in the same pair. This suggests little association between case rates by ZIP code and infection rates as estimated by serosurveillance.

There are several possible explanations for why seroprevalence may not track case rates. First, it is possible that our seroprevalence study provided a better representation of SARS-CoV-2 epidemiology than case rates. We used a highly sensitive assay (27) , and therefore likely detected positive individuals who were asymptomatic and never sought testing. At times, diagnostic testing in Chicago was unavailable or extremely restricted, and therefore even symptomatic individuals were not tested; these untested individuals would have been identified as having had COVID-19 with this antibody screen. Further, participants in the current study could be screened for antibodies by providing a sample they collect at home, and even when diagnostic testing was available, some individuals feared leaving their home to go to testing spaces. Along these same lines, serological antibody testing is a marker of past infections, whereas PCR diagnostic testing only detects active infections. If serology is indeed a more accurate representation of SARS-CoV-2 epidemiology, it would suggest that exposure to SARS-CoV-2 may have been more widespread than is indicated by case rates. This conclusion is also supported by a recent study comparing seroprevalence to case rates in 10 sites in the US (37).

Second, it is possible that, due to the sensitivity of the assay used in our study, we detected individuals who had lower doses of exposure to SARS-CoV-2 virus at the time of exposure, which may be associated with an asymptomatic or less intense clinical presentation (38, 39) . If this is true, then observed variation in case rates across ZIP codes may actually represent differences in severity of illness. Individuals with larger exposure doses may have an increased likelihood of experiencing symptoms and subsequently receiving diagnostic testing. Thus, individuals across these ZIP code pairs may not differ in their rates of actual exposure, but instead in their dose of exposure. If this is the case, it suggests that the use of serosurveillance studies to inform public health action may need to consider the disconnect between detection of any exposure and clinical risk. Quantitative antibody assays linking levels of antibody response to clinical presentation may be particularly useful for such research. At the same time, larger exposure doses would likely be tied to a close proximity between an infected and uninfected individual, such as those sharing a room in the same home. While 10 ZIP codes are too few for a formal statistical test, in our study a widely used metric of residential crowding (% of housing with 1.51+ occupants per room) showed little-to-no association with ZIP code seroprevalence. Of course, ZIP code level living density is not synonymous with density assessed at the level of a single home, so future research should assess number of people in home and in a shared bedroom.

A third possibility is that case rates are closely tied to symptoms, and symptoms are tied to older age and underlying comorbidities (40) , so even in conditions of constant levels of exposure/infection/transmission across neighborhoods, those with more social determinants of chronic diseases would tend to have higher case ratesassuming equal access to testing. When study ZIP codes were selected in April/May, testing as a proportion of the population was low across all ZIP codes (mean = 8.3% range 3.1-16.0%), but increased until at study completion most ZIP codes had more cumulative tests than residents. Comparisons of rates in Table 2 do not suggest that diagnostic testing rates are positively associated with seropositivity. Census markers of poor healthcare access also did not show a strong positive trend with seropositivity.

Admittedly, these are crude markers of presence of chronic diseases so future studies should examine additional markers. Overall, this pattern is consistent with more uniform spread of infections, including those that are asymptomatic, across Chicago ZIP codes than would be suggested by case surveillance data.

Our study also examined the relationship between individual characteristics and seropositivity. Differences by age, gender groups, and employment status stratified by possible exposure risk were not significant. As an epidemiological confirmation of the validity of the antibody assay used in this study, participants who self-reported a prior positive COVID-19 test were substantially more likely to be seropositive than those who did not (90.2% versus 16.1-17.2%). Most racial minority groups trended toward higher seropositivity, but the only two significant differences were significantly higher rates among Latinx compared to White and Asian, non-Latinx participants. These findings are consistent with case surveillance in Chicago, which indicated that at the time of the launch of data collection, case rates were surging in the Latinx community. As of alarming pattern is what inspired the focus of this study seeking to understand disparities in SARS-CoV-2 spread. Fortunately, these inequities in deaths from COVID-19 have shrunk over time as death rates overall have declined in the context of more effective prevention and treatment. This pattern is consistent with some partial role of pre-existing comorbidities in explaining racial disparities in COVID-19 disease and death; the magnitude or existence of such an effect is still contested in the existing literature and will require further research (3, 7, 8) . Such an effect would support repeating again the call to urgently address social determinants of health that produce inequities in chronic diseases that will exacerbate medical disparities when pandemics occur (41, 42) .

Findings must be considered in the context of study limitations. This was not a probability sample, but instead obtained through social and news media, community outreach, and employees of a large medical school. Our goal was not to provide population estimates of seroprevalence, rather we sought to look at relative rates within pairs of carefully selected adjacent ZIP codes with differing case rates. Nevertheless, our estimation of seroprevalence within ZIP codes may be biased by our sampling approach. For example, despite attempts to target recruitment from Black communities, the proportion of Black participants in the study underrepresented the demographics of Chicago. We sought to partially correct for this with sensitivity analyses that included demographic covariates and weighting. Further, individuals who opted to volunteer to participate when reading about the study through widespread coverage in local news, social media ads, or community outreach may not represent the entire community.

Some support for the representativeness of our sample comes from the large correlation between rates of a self-reported positive COVID test and CDPH positivity rate by zip code. Second, participants were required to self-collect a DBS sample.

Through well-produced videos and collection materials we hoped to minimize concerns, but selection biases may still have operated.

Our findings indicate that exposure to SARS-CoV-2 may be more consistent across neighborhoods within Chicago than was previously thought based on reported COVID-19 case rates. This suggests that factors other than differential seroprevalence may play a role in driving disparities in COVID-19 outcomes. One possibility is that preexisting chronic conditions are associated with greater risks of symptomatic infection, leading to higher rates of symptomatic illness and case detection in groups with higher rates of pre-existing chronic conditions. Another possibility is that the average dose of exposure is higher in some neighborhoods compared to others, leading higher rates of symptomatic illness and case detection in areas where the intensity of exposure is greater. Differences in viral dose may occur for a variety of reasons including differences in adherence to preventive behaviors, work environments, or living situations. Our results highlight the importance of investigating other factors besides differential exposure as potential drivers of inequity in COVID-19 outcomes. are included as they are the closest in time to the close of study data collection (11/23/2020) and therefore best represent the distribution of COVID-19 cases throughout the period of the study. 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

World Health Organization

White Counties Stand Apart: The Primacy of Residential Segregation in COVID-19 and HIV Diagnoses

COVID-19 mortality and neighborhood characteristics in Chicago

Social Determinants of Health Mediate COVID-19

Disparities in South Florida

Beyond the 405 and the 5: Geographic variations and factors associated with SARS-CoV-2 positivity rates in Los Angeles County

Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System

Black/African American Communities are at highest risk of COVID-19: spatial modeling of New York City ZIP Code-level testing results

Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19)

Infections and Transmission in a Skilled Nursing Facility

Community Transmission of SARS-CoV-2 at Two Family Gatherings

Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic

Presymptomatic Transmission of SARS-CoV-2

Population-based age-stratification seroepidemiological investigation protocol for COVID-19 infection

Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults

Profile of specific antibodies to SARS-CoV-2: The first report

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease

Viral Kinetics and Antibody Responses in Patients with COVID-19

Patterns and persistence of SARS-CoV-2 IgG antibodies in a US metropolitan site

Coronavirus Disease 2019 Test Results After Clinical Recovery and Hospital Discharge Among Patients in China

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients

Whole nucleocapsid protein of SARS-CoV-2 may cause false positive results in serological assays. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America

Testing for responses to the wrong SARS-CoV-2 antigen?

High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay

REDCap Consortium, The REDCap consortium: Building an international community of software partners

City Tech Collaborative. Chicago Health Atlas

Northwestern University

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

LABORATORY MS. ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY COVID-19 ELISA IGG ANTIBODY TEST Silver Spring, MS: Food and Drug Administration

A serological assay to detect SARS-CoV-2 seroconversion in humans

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States

Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity

COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics?

COVID-19 and comorbidities: Deleterious impact on infected patients

COVID-19 and the other pandemic: populations made vulnerable by systemic inequity

COVID-19 and the impact of social determinants of health

United States Postal Service

1-86.8) Prior COVID-19 testing 2 Never tested 1188

Chicago COVID-19 Cases, Tests, and Deaths by ZIP Code, Chicago Data Portal

Missing data for two participants

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.